Literature DB >> 29411189

Guillain-Barré syndrome following varicella-zoster virus infection.

Badrul Islam1,2, Zhahirul Islam3, Corine H GeurtsvanKessel4, Israt Jahan3, Hubert P Endtz3,5,6, Quazi D Mohammad7, Bart C Jacobs8.   

Abstract

We describe the frequency, clinical features, and electrophysiological and immunological phenotypes of Guillain-Barré Syndrome (GBS) patients treated at a single institution in Bangladesh who had preceding chicken pox (primary Varicella-zoster virus [VZV] infection) within 4 weeks of GBS onset. A literature review of GBS cases preceding VZV infection is also provided. Diagnosis of GBS was based on the National Institute of Neurological Disorders and Stroke criteria for GBS. Serum anti-VZV IgM and IgG antibodies were quantified by indirect chemiluminescence immunoassay (CLIA); anti-Campylobacter jejuni IgG, IgM, and IgA antibodies and anti-ganglioside GM1 IgM and IgG antibodies, by enzyme-linked immunosorbent assays. Neurophysiologic subtypes were categorized following the Hadden criteria. Of 536 patients with GBS, 7 (1.3%) had chicken pox within 4 weeks before GBS onset. Four of the seven cases were male (age range, 23 to 40 years old). All seven patients were bed-bound, six had sensory symptoms, and three required mechanical ventilation for respiratory failure. All seven patients had CSF albuminocytologic dissociation and evidence of demyelination in nerve conduction studies. Anti-VZV IgM antibodies were present and anti-GM1 and anti-Campylobacter jejuni lipo-oligosaccharides (LOS) were negative in all cases. All patients had excellent outcome at 1 year (able to run). A systematic literature review of GBS cases related to VZV revealed 39 previously reported patients with comparable clinical presentations and outcomes, of which 36 had neurophysiologic evidence of demyelination. VZV infection is associated with the demyelinating subtype of GBS, clearly distinct from the axonal form of GBS that predominate in countries like Bangladesh.

Entities:  

Keywords:  Chicken pox; Guillain-Barré syndrome; Herpes zoster; Shingles; Varicella zoster virus

Mesh:

Year:  2018        PMID: 29411189     DOI: 10.1007/s10096-018-3199-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   5.103


  54 in total

1.  Guillain-Barré syndrome after reactivation of varicella-zoster virus.

Authors:  L Roccatagliata; A Uccelli; A Murialdo
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

2.  Guillain-Barré syndrome in pregnancy: a rare complication of varicella.

Authors:  Manish Modi; Monica Singla; Neelam Aggarwal; Veenu Singla; Arvind Sharma
Journal:  Taiwan J Obstet Gynecol       Date:  2010-09       Impact factor: 1.705

3.  An uncommon association: chicken pox and Guillain-Barre syndrome.

Authors:  Turgay Cokyaman; Arzu Karli; Emine Tekin; Gulnar Sensoy; Haydar A Tasdemir
Journal:  J Infect Public Health       Date:  2014-11-18       Impact factor: 3.718

4.  Acute inflammatory demyelinating polyradiculoneuropathy following varicella.

Authors:  J M Murthy
Journal:  Postgrad Med J       Date:  1987-11       Impact factor: 2.401

5.  Haemophilus influenzae infection and Guillain-Barré syndrome.

Authors:  M Mori; S Kuwabara; M Miyake; M Noda; H Kuroki; H Kanno; K Ogawara; T Hattori
Journal:  Brain       Date:  2000-10       Impact factor: 13.501

6.  [Case of herpes zoster associated Guillain-Barré syndrome with a relapse of eruptions after intravenous immunoglobulin therapy].

Authors:  Yuriko Nagane; Kimiaki Utsugisawa; Daiji Obara
Journal:  Rinsho Shinkeigaku       Date:  2006-09

7.  Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh.

Authors:  Z Islam; B C Jacobs; A van Belkum; Q D Mohammad; M B Islam; P Herbrink; S Diorditsa; S P Luby; K A Talukder; H P Endtz
Journal:  Neurology       Date:  2010-02-16       Impact factor: 9.910

Review 8.  Guillain-Barré syndrome after varicella-zoster infection. Report of two cases.

Authors:  E A Sanders; A C Peters; J W Gratana; R A Hughes
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

Review 9.  Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.

Authors:  Nandini Sen; Ann M Arvin
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

10.  Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain-Barré and reactive arthritis patients.

Authors:  C W Ang; K Krogfelt; P Herbrink; J Keijser; W van Pelt; T Dalby; M Kuijf; B C Jacobs; M P Bergman; P Schiellerup; C E Visser
Journal:  Clin Microbiol Infect       Date:  2007-07-30       Impact factor: 8.067

View more
  16 in total

Review 1.  [Postvaccinal complications and management of suspected cases].

Authors:  Doris Oberle; Dirk Mentzer; Fabia Rocha; Renz Streit; Karin Weißer; Brigitte Keller-Stanislawski
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

2.  Varicella zoster virus infection in neurological patients in Bulgaria.

Authors:  Evelina Shikova; Antoniya Kumanova; Ivailo Tournev; Sashka Zhelyazkova; Evgenia Vassileva; Ivan Ivanov; Maria Pishmisheva
Journal:  J Neurovirol       Date:  2021-03-04       Impact factor: 2.643

3.  A 57 Year-Old Man With HIV Presenting With Severe Headache and Progressive Weakness.

Authors:  Andrew M Nguyen; Jenna A Decker; Janae E Dupuis; Ann A Little; Lauren D Ottenhoff; Venkatakrishna Rajajee; Kyle M Sheehan; Craig A Williamson
Journal:  Neurohospitalist       Date:  2021-01-20

4.  Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome.

Authors:  Aileen Y Chang; Rebecca Lynch; Karen Martins; Liliana Encinales; Andrés Á Cadena Bonfanti; Nelly Pacheco; St Patrick Reid; Osvaldo E Lara Sarabia; Henry J González Torres; Stella Mejia Castillo; Onaldo Barrios Taborda; Magda Alarcon Gomez; Brenda Guerra Duran; Victor Martinez Giraldo; Angélica Benitez Ospino; Alexandra Porras; Alejandro R Mendoza; Grace Mantus; Guangzhao Li; Jin Peng; Priyanka Kamalapathy; Lil G Avendaño Echavez; Kimberly A Dowd; Monica Rengifo-Pardo; Pedro Pablo Barraza; Dennys Jiménez Hernàndez; Andrés González Coba; Katya De La Hoz Mendoza; Jeffrey M Bethony; Gary L Simon
Journal:  Emerg Microbes Infect       Date:  2018-08-22       Impact factor: 7.163

Review 5.  Clinical Features of Varicella-Zoster Virus Infection.

Authors:  Peter G E Kennedy; Anne A Gershon
Journal:  Viruses       Date:  2018-11-02       Impact factor: 5.048

6.  Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: a 10-year retrospective study.

Authors:  Safiyyah Asiri; Waleed A Altwaijri; Duaa Ba-Armah; Ahmed Al Rumayyan; Muhammad T Alrifai; Mahmoud Salam; Adel F Almutairi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-03-01       Impact factor: 2.570

Review 7.  Diagnosis and management of Guillain-Barré syndrome in ten steps.

Authors:  Sonja E Leonhard; Melissa R Mandarakas; Francisco A A Gondim; Kathleen Bateman; Maria L B Ferreira; David R Cornblath; Pieter A van Doorn; Mario E Dourado; Richard A C Hughes; Badrul Islam; Susumu Kusunoki; Carlos A Pardo; Ricardo Reisin; James J Sejvar; Nortina Shahrizaila; Cristiane Soares; Thirugnanam Umapathi; Yuzhong Wang; Eppie M Yiu; Hugh J Willison; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2019-09-20       Impact factor: 42.937

8.  Guillain-Barré syndrome in the early post-partum period following COVID-19 infection.

Authors:  A Abdelnasser; M Mostafa; A Hasanin; A El-Sakka; H Hassanein
Journal:  Int J Obstet Anesth       Date:  2021-05-01       Impact factor: 2.603

Review 9.  SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms.

Authors:  Shahrzad Shoraka; Maria Lucia Brito Ferreira; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

Review 10.  Cannabidiol and Other Cannabinoids in Demyelinating Diseases.

Authors:  Carmen Navarrete; Adela García-Martín; Alain Rolland; Jim DeMesa; Eduardo Muñoz
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.